Hector David Inzunza
30 works · 5,740 citations · h-index 13
Top works
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
- Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
- Programmed death-ligand 1 (PD-L1) expression in various tumor types
- CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma
- Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma
- The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice
- An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1
- Mutations in the Hedgehog Pathway Genes SMO and PTCH1 in Human Gastric Tumors
- Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
- Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
- PS-150-Evidence for the presence of infectious virus in the serum from chronic hepatitis B patients suppressed on nucleos (t)ide therapy with detectable but not quantifiable HBV DNA
- PD-L1 Detection and Assay Performance in Squamous Cell Carcinoma of the Head and Neck Using PD-L1 IHC 28-8 pharmDx
- Assay performance of the PD-L1 IHC 28-8 pharmDx assay in squamous cell carcinoma of the head and neck (SCCHN).
- Development of a diagnostic PD-L1 immunohistochemical assay for nivolumab therapy in urothelial carcinoma.
- ABBV-303 Is an NK-cell Engager Specific for c-Met–Expressing Tumors
- Supplementary Figure 2 from ABBV-303 Is an NK-cell Engager Specific for c-Met–Expressing Tumors
- and Metastasis of Fibrosarcoma Tumors in Athymic Mice